导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 32.13% | 114/4773 |
| 近一周 | 2.41% | 98/5465 |
| 近一月 | -6.87% | 4357/5421 |
| 近一季 | -10.14% | 3702/5231 |
| 近半年 | 23.87% | 130/4920 |
| 近一年 | 37.81% | 146/4394 |
| 近两年 | 200.86% | 85/2954 |
| 近三年 | 128.71% | 60/2253 |
| 成立以来 | 237.98% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-5.01% 3745/4961 |
106.24% 70/5312 |
- - |
- - |
| 2025 | 43.91% 647/4813 |
3.38% 1095/3635 |
-0.27% 2867/4076 |
51.45% 278/4524 |
-7.84% 3843/4813 |
| 2024 | 25.11% 270/3463 |
-11.51% 2434/2808 |
0.64% 566/3014 |
18.03% 1072/3129 |
19.03% 57/3463 |
| 2023 | -3.92% 659/2656 |
18.53% 158/2280 |
-8.43% 1993/2385 |
-10.12% 1957/2515 |
-1.51% 335/2655 |
| 2022 | -39.13% 1767/2207 |
-23.60% 1738/1919 |
-0.46% 1626/2016 |
-20.26% 1844/2113 |
0.38% 1504/2208 |
| 2021 | 29.00% 78/1822 |
-10.15% 1113/1255 |
41.75% 15/1330 |
-4.94% 755/1466 |
6.55% 211/1822 |
| 2020 | 52.81% 153/1250 |
10.06% 20/1028 |
31.36% 41/1067 |
-1.63% 1072/1164 |
7.44% 712/1184 |
| 2019 | - - |
- - |
- - |
24.94% 2/850 |
20.71% 2/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 国泰CES半导体芯片ETF VS. 长安沪深300非周期A(740101) |